medigraphic.com

2007, Number 1

<< Back Next >>

Arch Cardiol Mex 2007; 77 (1)

C-reactive protein: Cardiovascular issues of an acute-phase protein

Amezcua-Guerra LM, Springall VR, Bojalil PR

Language: Spanish
References: 38
Page: 58-66
PDF size: 101.23 Kb.


ABSTRACT

C-reactive protein (CRP) is a nonspecific acute phase protein that has been used as an inflammatory marker for decades. More recently, it has been proposed as a predictor of cardiovascular disease (myocardial infarction, stroke, peripheral artery disease and sudden heart death). Physiologic functions of CRP as an anti-inflammatory scavenger molecule have begun to emerge. CRP binds to damaged lipoproteins and facilitates their removal by phagocytes, partially activating the complement cascade. Increased levels of CRP may result in direct effects on vascular cells, including the induction of cytokines and prothrombotic factors. Although previous studies suggested a potent independent association of CRP levels with cardiac events, the strength of this association has been shown to be weaker than previously reported in a recent large meta-analysis and in prospective studies. Therapy with statins in patients with coronary artery disease has been found to reduce adverse outcomes in association with reductions of CRP levels, independently of their effects on the lipid profile.


REFERENCES

  1. Pepys MB, Baltz ML: Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141-212.

  2. Baltz ML: Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci 1982; 389: 49-75.

  3. Gershov D, Kim S, Brot N, Elkon KB: C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implication for systemic autoimmunity. J Exp Med 2000; 192: 1353-63.

  4. Pepys MB, Rowe IF, Baltz ML: C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol 1985; 27: 83-111.

  5. Bickerstaff MCM: Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-7.

  6. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993; 91: 1351-7.

  7. Kushner I: Acute phase response. Clin Aspects Autoimmunity 1989; 3: 20-30.

  8. Hutchinson WL, Koenig W, Frhlich M, Sund M, Lowe GDO, Pepys MB: Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000; 46: 934-8.

  9. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.

  10. Ballou SP, Kushner I: Laboratory evaluation of inflammation. En Ruddy S, Harris ED, Sledge CB (Eds): Kelley’s Textbook of Rheumatology. Philadelphia, JB Saunders Company, 2001: 697-703.

  11. De Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB: Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239-43.

  12. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheuth FW, et al: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.

  13. Griselli M, Herbert J, Hutchinsin WL, Taylor KM, Sohail M, Krausz T, et al: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733-40.

  14. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP: C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55: 445-51.

  15. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. N Engl J Med 2002; 347: 1557-65.

  16. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.

  17. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy-middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.

  18. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al: Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA 2002; 288: 980-7.

  19. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al: C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-90.

  20. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.

  21. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.

  22. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.

  23. Wilson PW, Nam BH, Pencina M, D’Agostino RB Sr, Benjamin EJ, O’Donnell CJ: C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165: 2473-8.

  24. Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955-9.

  25. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE: Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326-33.

  26. Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low-density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7.

  27. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6.

  28. Ballou SP, Lozanski G: Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-8.

  29. Williams TN, Zhang CX, Game BA, He L, Huang Y: C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcgRII and extracellular signal-regulated kinase pathway: An implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004; 24: 61-6.

  30. Blaschke F, Bruemmer D, Yin F, Takata Y, Wang W, Fishbein MC, et al: C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004; 110: 579-87.

  31. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.

  32. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 8439-44.

  33. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.

  34. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.

  35. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.

  36. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.

  37. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al: Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217-21.

  38. Kitsis RN, Jialal I: Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med 2006; 355: 513-5.




2020     |     www.medigraphic.com